Milestone’s plans to resubmit heart drug; Alvotech’s $166M offer; Vaccine biotech raises $11M

Mile­stone Phar­ma­ceu­ti­cals de­tails plan to re­sub­mit etri­pamil to the FDA in Q2: For its ex­per­i­men­tal treat­ment for parox­ys­mal supraven­tric­u­lar tachy­car­dia, the com­pa­ny will now “re­struc­ture the da­ta sets” for tim­ing around ad­verse events and “re­for­mat cer­tain da­ta files” for FDA analy­ses. Mile­stone had re­port­ed a refuse-to-file ac­tion in De­cem­ber. Its stock $MIST was up about 22% on Mon­day morn­ing. — Jaimy Lee

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.